Terry Rosen, Ph.D. (CEO)

Terry has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop small-molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion. Prior to Flexus, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. He was named Amgen Washington site head in 2006, transitioned to a leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011. He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen’s large and small molecule drug discovery efforts.

Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the SAB and leadership committees of the University of Michigan Life Sciences Institute, the Board of Trustees of the UC Berkeley Foundation, the Caltech Biology & Bioengineering Chair’s Council and the Board of the California Life Sciences Association.​

Juan Jaen, Ph.D. (President)

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Dr. Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert.

Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Dr. Jaen has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.

William J. Grossman, M.D., Ph.D. (CMO)

Dr. Grossman has over 25 years of extensive experience leading successful global clinical organizations. Bill joins Arcus from Bellicum Pharmaceuticals, where he served as Chief Medical Officer and was responsible for the company’s clinical development, regulatory affairs, clinical operations, and medical affairs organizations. Prior to Bellicum, Dr. Grossman was the Global Group Medical Director for Cancer Immunotherapy at Genentech, where he led the clinical development of TECENTRIQ® in gastrointestinal cancers and of cancer immunotherapy combinations across all solid tumor types. Bill designed and led the Phase 1b/2 MORPHEUS platform, a rapid and efficient paradigm for the evaluation of cancer immunotherapy combinations. Before joining Genentech, he led the development and execution of the U.S. & Global medical affairs strategy for the oncology franchise at AbbVie.  Previously, Dr. Grossman served as Senior Vice President, Research & Clinical Development at Biothera, where he oversaw all discovery and clinical development efforts in oncology and immunology. In addition, Dr. Grossman has held leadership positions in research, clinical development, and medical affairs at Baxter Healthcare and Merck & Co., where he was involved in the clinical evaluation of anti-cancer vaccines, immunomodulatory agents, small molecules and biologics for oncology.

Prior to joining the industry, Dr. Grossman held various positions with the Children’s Hospital of Wisconsin/Medical College of Wisconsin where he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics, and Director of the Hematology/Oncology/Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. Dr. Grossman earned a B.A. in both Biology and Chemistry from University of St. Thomas, St. Paul, (Minnesota), Magna Cum Laude and his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical training in the Division of Pediatric Biology/Medicine at the Washington University School of Medicine.

Eric Hoefer (CCO)

Eric has over 20 years in biopharma, where he has been instrumental to the development and commercialization of 15 new medicines, including Avastin®, Tarceva®, Tecentriq®, and Imfinzi®. His diverse experience spans global product strategy, global marketing, product development, and U.S. marketing and sales leadership. Mr. Hoefer was most recently at AstraZeneca, where he led Immuno-Oncology (IO) Global Marketing and launched Imfinzi as the first immuno-oncology medicine approved in the curative-intent lung cancer setting.  Prior to joining AstraZeneca, Mr. Hoefer launched seven new medicines during an approximately 14-year tenure with Roche/Genentech.  From 2015-2017, Mr. Hoefer co-led the creation of Roche’s Phase 1b/2 IO platform (MORPHEUS) to adaptively assess and accelerate novel combination approvals across seven tumor types. Also, during his tenure, Mr. Hoefer led the commercial development for late-stage GI oncology assets. Mr. Hoefer began his biopharma career in primary care and specialty care sales for GlaxoWellcome. In 2002, as a Congressional Health Policy Analyst for the Chairman of the House Ways & Means Committee, he was involved in developing the Medicare Modernization Act, including Part B reform and the Part D prescription drug benefit.

Mr. Hoefer received Master’s degrees in Business Administration and Public Policy from Duke University. In addition, Mr. Hoefer holds Bachelor of Science degrees in Molecular Biology and Economics from Duke University.

Carolyn Tang (General Counsel)

Carolyn is an attorney with broad expertise in transactions, intellectual property, securities and corporate governance (US and Europe). Prior to joining Arcus, Carolyn was responsible for strategic transactions, securities and corporate governance at Medivation, until its acquisition by Pfizer.

Prior to Medivation, Carolyn held positions of increasing responsibility at InterMune, where she oversaw the company’s global IP portfolio and supported the approval and commercialization of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the EU, Canada and US. She helped establish and administer InterMune’s European subsidiaries and assisted in public offerings of common stock and convertible senior notes raising nearly $850 million in the 4 years prior to the company’s acquisition by Roche.

Carolyn received a B.A. degree in Molecular and Cell Biology with an emphasis in Neurobiology from the University of California at Berkeley and a J.D. degree from Santa Clara University School of Law.

Jay Powers, Ph.D. (SVP, Drug Discovery)

Jay has had a remarkable track record of success in drug discovery in the biopharmaceutical industry, spanning a period of nearly 20 years. Most recently, Jay was Vice President of Drug Discovery at Flexus Biosciences and then FLX Bio. During his tenure at Flexus, he oversaw drug design efforts in the IDO Inhibitor program, which was the main driver for the company’s acquisition by BMS in early 2015. Previously, he was Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Jay was involved in the discovery and clinical progression of 7 novel drug candidates in the immunology area, the most advanced of which is currently undergoing Phase 3 evaluation in ANCA-associated renal vasculitis. Prior to joining ChemoCentryx in 2007, Jay was at Tularik and then Amgen (after its acquisition of Tularik in 2004), most recently as Scientific Director in Medicinal Chemistry. Jay began his career in 1996, working in the anti-infectives area at Abbott Laboratories.

Jay received a B.S. degree in Biochemistry and a Ph.D. in Organic Chemistry from the University of Minnesota and completed postdoctoral studies in the laboratories of Professor Gilbert Stork at Columbia University. Jay is an inventor on over 50 issued U.S. patents and has published extensively in the areas of medicinal and synthetic organic chemistry. Over the course of his career, Jay has been responsible for the discovery of 16 compounds that have gone into clinical development in the oncology, immunomodulation, inflammation, antiviral and metabolic disease areas.

Jason Barker

Jason Barker (VP, Finance and Principal Financial Officer)

Jason is a finance executive with over 25 years of experience that includes building and leading corporate finance and accounting functions within public and private companies. His experience encompasses work with start-ups, mid-cap and Fortune 500 companies primarily in the areas of life science and technology. Prior to joining Arcus, Jason was Vice President of Finance at Audentes Therapeutics where he was responsible for finance, accounting, audit, financial reporting, treasury, risk management and oversight of certain legal functions. During his time at Audentes, Jason led the company’s operational readiness leading up to a successful IPO in 2016 and also served as CFO for the company’s international subsidiaries. Prior to Audentes, Jason served as Principal and Senior Advisor at Bauer York LLC, providing finance consulting services to numerous corporations within Silicon Valley. During his time at Bauer York, Jason served as interim CFO for Zosano Pharma during their preparations for an IPO and as an advisor to various other companies. From 2004-2011, Jason held several positions of increasing responsibility at ARYx Therapeutics including serving as Head of Finance and Principal Accounting Officer while contributing to the company’s successful IPO in 2007.

Jason earned a B.A. in Finance, Accounting, and Business Law, with honors, from the University of Texas at Arlington.

Katherine Bock (VP, Investor Relations and Corporate Strategy)

Kaytee has been in the life sciences industry over 15 years. Most recently, Kaytee was Vice President Investor Relations & Corporate Communications at Adverum Biotechnologies.  Prior to Adverum, Kaytee was at Nevro, where she led corporate development and investor relations as well as chief of staff for the chief executive officer. While at Nevro, she helped execute Nevro’s successful initial public offering in 2014, as the first medical device company to price above their range since 2007, and helped lead subsequent financings, including the largest medtech follow-on in over 10 years and a convertible raise. Before Nevro, Kaytee worked at Lazard as an associate in the healthcare investment banking group, where she focused on M&A advisory roles and capital market transactions. Previously, Kaytee worked at Genentech as a market planning manager associate in the competitive intelligence group, where she was responsible for assessing the competitive landscape for pipeline products.  Earlier in her career, Kaytee conducted biotechnology research at Genentech in the small molecule translational oncology group and in Corgentech’s oncology group.

Kaytee earned a B.S. in Applied Mathematics at San Francisco State University and an M.B.A. from The Wharton School at the University of Pennsylvania. She is also active in the community with the Board of the Northern California Chapter of the National Multiple Sclerosis Society as the former Treasurer.

Patty Carlos (VP, Regulatory Affairs)

Patty has over 20 years of comprehensive experience in regulatory affairs encompassing early drug development through regulatory approval and post marketing. Her expertise includes work in Human Immunodeficiency Virus (HIV) and Chronic Kidney Disease (CKD), with a concentration in immuno-oncology and hematology. Patty has been responsible for securing regulatory approvals for the successful global development of eight oncology compounds, including both small and large molecule compounds.

Most recently, Patty led the development and implementation of global regulatory strategy for Bellicum Pharmaceuticals and BeiGene, Inc. During her tenure at BeiGene, Patty was responsible for the establishment and growth of the regulatory organization for the Company’s U.S. business and was a deciding member of global steering committees for two strategic partners. Prior to BeiGene, Patty was the director of regulatory affairs at Medivation, Inc. (Pfizer, Inc.) where she was directly responsible for the coordination and execution of the global regulatory filing for TALZENNA®. Patty also held roles of increasing responsibility at Gilead Sciences, Inc. as the filing lead for Odefsey® and Descovy®, Vifor Pharma Management Ltd. and the Ministry of Health Services, Province of British Columbia.

Her expertise spans regulatory interactions with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Swedish Medical Products Agency (MPA), Netherlands: Medicines Evaluation Board (MEB), Germany: Paul-Ehrlich-Institut (PEI), Spanish Agency of Medicines and Medical Devices (AEMPS), and United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA), China: the National Medical Products Administration (NMPA), Japan:  Pharmaceuticals and Medical Devices Agency (PMDA).

Patty holds an Advanced Graduate Diploma in Biology and Bachelor of Science degree in Biology both from the Memorial University of Newfoundland.

Yvonne Gehring (VP, Human Resources & Operations)

Yvonne is a seasoned Human Resources professional with more than 30 years of experience in the biopharmaceutical industry. Prior to joining Arcus in 2016, she consulted with multiple companies to develop and implement HR strategies and programs. Previously, Yvonne was Sr. Director and Director of Human Resources at ChemoCentryx, Inc. from 2007-2014, where she was responsible for staffing, employee relations, compensation & benefits, and organizational development. From 2001-2007, Yvonne was Director of Human Resources at Theravance, Inc., where she led an HR team during a period of exponential growth, as the organization transitioned from a pre-IPO stage through an IPO. She has also held Human Resources management positions at Inhale Therapeutic Systems and SyStemix, Inc. (a Novartis subsidiary). Yvonne began her career in Human Resources at Genentech, Inc., where she worked for 7 years. Yvonne served as Vice-Chair of the BIO Human Resources Committee in 2009.

Kartik Krishnan, M.D., Ph.D. (VP, Clinical Development)

Kartik has extensive expertise developing oncology therapies.  His experience spans the biopharma industry, academia and clinical setting.

Kartik joins Arcus from Astex Pharmaceuticals, Inc., where he was most recently Executive Medical Director of Clinical Research, leading the medical monitoring group, and executing clinical trials from IND submission through pivotal phase 3 in hematologic malignancies.  Prior to Astex, Kartik had been at Genentech, Inc. leading the development team of TECENTRIQ® in hematologic malignancies. In addition, at Genentech in the Signaling franchise, he worked on multiple small molecules including Erivedge®, Zelboraf® and COTELLIC®.  Kartik began his industry career at Amgen Inc. where he worked on development of Vectibix® in colon cancer and non-small cell lung carcinoma (NSCLC).  During his tenure at Amgen, Kartik worked in the pharmacovigilance group, supporting trabananib (AMG386). Kartik also held positions of increasing responsibility at BioMarin, working on TALZENNA® in breast cancer and other solid tumors, and at FivePrime Therapeutics, working on immuno-oncology assets in multiple tumor types including gastric and rare tumors.

Kartik served as Assistant Professor at the University of Arizona in the Department of Pediatrics’ Division of Hematology/Oncology, producing a number of first-author publications on the molecular biology of tumorigenesis and metastasis and has presented at multiple global oncology conferences both clinical and scientific.

Kartik received a B.A. degree in History (with Distinction) from the University of Virginia and M.D./Ph.D. at Columbia University’s College of Physicians and Surgeons in New York City.  While at Columbia, Kartik performed basic molecular biology research on Jak/STAT signaling in the interferon pathway.  Kartik did his residency in Pediatrics at UCLA and his fellowship in Pediatric Hematology/Oncology at the Johns Hopkins-NCI program, focusing on the biology of pediatric solid tumors, especially related to metastasis.

Melissa C. Paoloni, DVM, DACVIM-O (VP, Medical Affairs & Clinical Partnerships)

Dr. Paoloni has been engaged in all aspects of clinical trial design for the past 15 years. Prior to joining Arcus, Melissa was Director of Clinical Trial Science at Berry Consultants. While at Berry Consultants, she co-founded the Clinical Trial Strategy Team, whose mission was to accelerate the clinical development process across all therapeutic areas. During her tenure, Dr. Paoloni was an integral part in the design, construction and implementation of two large scale, phase 2-3 trials in glioblastoma (GBM AGILE) and metastatic pancreatic cancer (Precision Promise), as well as working with many industry clients on strategic planning and regulatory strategy. In 2013 Melissa joined QuantumLeap Healthcare Collaborative as the Executive Director of Clinical Research for the I-SPY Program. Dr. Paoloni facilitated partnerships with pharmaceutical companies, regulatory agencies, and institutions for the I-SPY 2 TRIAL, a phase 2 trial to evaluate novel drugs in the neoadjuvant setting for women with high-risk breast cancer. She was also involved in the expansion of the I-SPY Program with the development of the I-SPY phase 1 network and the design of the I-SPY 3 TRIAL.

Dr. Paoloni, received her Doctor of Veterinary Medicine at Tufts University and completed her residency in Medical Oncology at the University of Wisconsin-Madison. She then joined the National Cancer Institute (NCI) for her post-doctoral fellowship, where she pursued a Master’s degree in Clinical Trial Design from Duke University. While at the NCI for almost 10 years as a Staff Scientist, she ran a pre-clinical modeling group focused on oncology drug development that worked with many academic, pharmaceutical and biotechnology partners. Her area of focus was in early phase drug development and translational research.

Andrew Pennell, Ph.D. (VP, Preclinical Development)

Andrew has been involved in all aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. and U.K. for more than 20 years, establishing medicinal chemistry and preclinical development departments and leading discovery and preclinical development teams in a variety of therapeutic areas (e.g., oncology, autoimmune, inflammatory, bacterial, viral, cardiovascular, metabolic and CNS diseases). Prior to joining Arcus, Andrew was Executive Director of Preclinical Development and, before that, Director of Medicinal Chemistry at ChemoCentryx, where he was centrally involved in the discovery and clinical development of nine novel drug candidates, several of which completed Phase 2 trials and two of which have entered Phase 3 development. Between 1993 and 2002, Andrew held various scientific management positions, first at GlaxoWelcome and then as Director of Medicinal Chemistry at Genesoft Inc.

Andrew’s responsibilities have included leadership of medicinal chemistry, DMPK, preclinical safety evaluation and chemistry / pharmaceutical development (CMC)Andrew holds a B.Sc. (Hons) degree in Chemistry and a Ph.D degree in Organic Chemistry from Imperial College London and conducted postdoctoral research at Columbia University under the guidance of Professor Gilbert Stork.  Andrew is an inventor on more than 50 issued U.S. patents.

Ulrike Schindler, Ph.D. (VP, Scientific Affairs)

Uli has spent more than 20 years in the biopharmaceutical industry and has led research organizations in the U.S. and Germany. In her most recent industry position, until 2013 Uli led the Biologics Discovery function at Amgen, a group of about 200 FTE which was responsible for all of Amgen’s large-molecule drug discovery efforts. In 2000, Uli established and led the Regensburg (Germany) technology site for Tularik, which was acquired by Amgen in 2004. She and her team were responsible for all small-molecule high-throughput screens for Tularik and subsequently Amgen. During this time, the team identified small-molecule leads for numerous drug targets involved in various therapeutic indications such as cancer, asthma, allergy, metabolic disorders and neurological diseases. Concurrently with her assignment in Regensburg, Uli also led Amgen’s Alantos Pharmaceutical AG in Heidelberg (Germany), a specialized team of medicinal chemists.

Prior to Amgen, Uli held various positions at Tularik, where she established and led various Immune Disorders projects between 1993 and 2000. Uli obtained her Ph.D. degree in Biology from the University of Freiburg (Germany) in 1992. From 1987 to 1993, she was a visiting scientist at the University of Pennsylvania, where she focused her research on the regulation of gene transcription. Uli has co-authored over 40 scientific publications and book chapters.

Tim Sullivan, Ph.D. (VP, Business Development)

Tim has been involved in multiple aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. for more than 15 years, leading discovery and pharmacology teams in a variety of therapeutic areas (e.g., oncology, autoimmune, inflammatory, metabolic and CNS diseases) as well as being involved in groups focused on the external identification of novel technologies and assets suitable for in-licensing and/or acquisition. Prior to joining Arcus, Tim was a Senior Director in the External R&D Innovation (ERDI) group at Pfizer where he focused on identifying new Immuno-Oncology opportunities across all therapeutic modalities, as well as managing the global alliances with Servier and Cellectis focused on the discovery and development of allogeneic CAR-T cell products. Before Pfizer, Tim was a Director in the New Frontier Science group at Takeda, where he primarily focused on identifying and funding very early-stage technologies being developed in academic settings to determine utility in accelerating drug discovery and development.

Prior to Takeda, Tim held various scientific management roles, first at Tularik/Amgen and then as Director of Biology at ChemoCentryx. Tim holds a B.A. degree from the University of Notre Dame and a Ph.D. degree in Cellular and Molecular Biology from the University of California, Berkeley where he trained in the laboratory of Dr. James Allison.

Nigel Walker, Ph.D. (VP, Protein Science)

Nigel maintains a passion for drug discovery and has more than 30 years of experience in the pharmaceutical, biotechnology and chemical industries. Prior to joining Arcus, Nigel was the Executive Director of Amgen’s Molecular Structure & Characterization division leading 80+ staff engaged in providing analytical & biophysical support for all of Amgen’s large and small molecule drug discovery programs. Throughout his career, Nigel has repeatedly utilized 3D structural data in support of drug discovery projects; he directed Amgen’s structural analysis of the binding modes of antibody inhibitors of PCSK9, including the marketed product Repatha™ (evolocumab) for the treatment of hypercholesterolemia. Nigel joined Tularik in 1998 as Director of Structural Biology and established structural biology and computational chemistry groups to support a diverse array of small molecule drug discovery projects. In 2004, he transitioned to Amgen following their acquisition of Tularik.

Nigel started his industrial career in 1985 at BASF AG in Germany. As their first protein crystallographer, Nigel built their facility and drove the research to produce key first-in-class 3D structures for proteins such as TNF-alpha and caspase-1. Over the course of his career, Nigel has worked on a broad portfolio of molecular targets with a variety of therapeutic modalities and is a co-author on over 100 peer reviewed articles and a co-inventor on 15 issued U.S. patents. Nigel holds B.Sc. (Hons) and Ph.D. degrees in Biochemistry from the University of Bristol, U.K.

Matt Walters, Ph.D. (VP, Biology)

Matt has been involved in drug discovery research for 14 years, responsible for leading both preclinical and translational science teams in multiple therapeutic areas. Prior to joining Arcus, Matt was at Flexus Biosciences, subsequently FLX Bio, where he held the position of Director of Biology. In this role Matt was key in establishing both the Biology and the Vivarium functions from the ground up, enabling the successful prosecution of the IDO program. Before Flexus, Matt held positions of increasing responsibility at ChemoCentryx, where he led efforts in drug discovery and translational science for numerous programs as well as representing the company in global alliances.

Matt holds a B.Sc (Hons) from the University of Bangor and a Ph.D. (Pharmacology) from the National Heart and Lung Institute, Imperial College London. He has authored/co-authored multiple publications in basic biology and drug discovery. As a successful leader of multiple programs his efforts have driven multiple therapeutic agents into clinical development.

Steve Young, Ph.D. (VP, Technology)

Steve has been in scientific, technical and leadership roles across Europe and the US since 1993, most recently as VP of Technology at Flexus Biosciences (subsequently FLX Bio). He was the first scientist at Flexus and spearheaded a ground-up build of the biology and IT/informatics functions, including hiring the team and establishing the SAR data infrastructure which enabled the successful IDO inhibitor program. Previously, as Executive Director at Amgen, heading the Discovery Technologies Department, Steve led a group of 110 scientists across five geographical sites to enact key technical functions including Research Automation and Technology, Materials Management, HTS, Bioassay Technology and Target Discovery/Validation. Steve started at Amgen in 2004, following the acquisition of Tularik, where he had been leading the Lead Discovery Function (Small Molecule and Genomic Screening, Automation and SAR data generation). He moved to Seattle to establish the first automated screening laboratory at Amgen, Washington in 2006.

In 2008 he moved again to Massachusetts to serve as the inaugural site head at Amgen’s east coast research hub in Cambridge, focusing on Amgen’s growth in a key scientific locale and acting as Amgen’s senior representative for academia, industry and government affairs. Prior to moving to the U.S. in 2001, Steve headed the HTS Department at Roche U.K., having started his career earlier at Glaxo. Steve holds B.Sc. (Hons) and Ph.D. degrees in Biochemistry from the University of Bristol and a diploma in Business Administration from the Open University. He is currently on the Board of Directors of the Society for Laboratory Automation and Screening.